Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: KBL Merger Corp. IV KBLM

180 Life Sciences Corp. Expands IP Portfolio with EU, U.S., and Chinese Patents

The company’s patent portfolio includes its own intellectual property and exclusive worldwide licenses, including in the U.S., Canada, Europe, Australia, Hong Kong, and China 180 Life Sciences is in the final stages of its merger process with KBL Merger Corp. … Continue reading

Posted in 180 Life Sciences Corp., KBL Merger Corp. IV KBLM | Leave a comment

180 Life Sciences Corp. Bringing Hope to Those Afflicted by Dupuytren’s Disease and Other Inflammatory Conditions

180 Life Sciences is a clinical-stage biotechnology company developing anti-tumor necrosis factor (“TNF”) therapies to treat a variety of inflammatory conditions. Phase 2b/3 clinical trials on fibrosis and inflammation-causing TNF irregularity are currently underway with first results expected in 2021 … Continue reading

Posted in 180 Life Sciences Corp., KBL Merger Corp. IV KBLM | Leave a comment

MissionIRNewsBreaks – 180 Life Sciences Corp. Announces New Board Appointments

KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC) that previously entered a definitive agreement to acquire 180 Life Sciences, a clinical-stage biotechnology company, recently announced … Continue reading

Posted in 180 Life Sciences Corp., KBL Merger Corp. IV KBLM | Leave a comment

MissionIRNewsBreaks – 180 Life Sciences Corp. Setting the Stage for Success in Bringing Novel Products to Market

180 Life Sciences, a clinical-stage biotechnology company, is focused on research to solve one of the world’s most significant drivers of disease – inflammation. The company currently has three programs for the development of novel drugs in the areas of … Continue reading

Posted in 180 Life Sciences Corp., KBL Merger Corp. IV KBLM | Leave a comment

MissionIRNewsBreaks – 180 Life Sciences Corp. Advancing Lead Program, Plans Additional Clinical Trials

180 Life Sciences, a clinical-stage biotechnology company, is dedicated to producing solutions designed to battle inflammation when the body’s natural processes go awry. The company’s primary focus is to treat fibrosis and inflammation using anti-TNF therapy, designed to block the … Continue reading

Posted in 180 Life Sciences Corp., KBL Merger Corp. IV KBLM | Leave a comment

180 Life Sciences Corp. Leading Research into Novel Drug Therapies Expected to Produce First Results of Phase 2b/3 Trial in 2021

Anti-inflammatory therapeutics market to generate revenues of $191.42 billion through 2027 Novel drug therapy for Fibrosis and Anti-TNF trials being conducted by Professor Sir Marc Feldmann, who already developed one of the most commonly used anti-TNF medications, Remicade The number … Continue reading

Posted in 180 Life Sciences Corp., KBL Merger Corp. IV KBLM | Leave a comment

KBL Merger Corp. IV (NASDAQ: KBLM) (NASDAQ: KBLMR) (NASDAQ: KBLMW) Fulfilling IPO Goal Through Merger With 180 Life Sciences Corp.

KBL Merger Corp. IV is set to finalize the acquisition of 180 Life Sciences Corp. during Q4 2020 180 Life Sciences Corp. has several ongoing programs at different stages of development, with the leading candidate in Phase 2b/3, helping mitigate … Continue reading

Posted in 180 Life Sciences Corp., KBL Merger Corp. IV KBLM | Leave a comment